Dose‐Optimization of a Novel Co‐Formulated Triple Combination Antimalarial Therapy: Artemether‐Lumefantrine‐Amodiaquine
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Artemisinin‐based combination therapy (ACT) is the first‐line therapy for uncomplicated falciparum malaria, but artemisinin resistance in Asia and now sub‐Saharan Africa is threatening our ability to control and eliminate malaria. Triple‐ACTs have emerged as a viable alternative treatment to combat declining ACT efficacy due to drug‐resistant malaria. In this study, we developed and evaluated an optimal fixed‐dose regimen of artemether‐lumefantrine‐amodiaquine through population pharmacokinetic modeling and simulation. Three published population‐based pharmacometric models and two large cohorts of observed adult subjects and pediatric malaria patients were used to simulate pharmacokinetic profiles of different dosing strategies. Based on simulated total exposure and peak concentrations, an optimal dose regimen was developed resulting in an extension of the current 4 weight bands to a total of 5 weight bands to generate equivalent exposures in all body weight groups and minimize the fluctuation in exposure between patients. The proposed drug‐to‐drug ratio of artemether‐lumefantrine‐amodiaquine (20:120:40 mg) was kept constant throughout the dosing bands in order to simplify manufacturing, implementation, and further development of a fixed‐dose co‐formulated product.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“If ART-R spreads further, AL efficacy could be compromised, a risk heightened by heavy reliance on lumefantrine in current ACTs and next-generation combinations such as the triple ACT AL–amodiaquine and ganaplacide–lumefantrine21,23.”
From Genomic surveillance reveals co-occurrence of Plasmodium falciparum drug resistance variants across diverse transmission settings in Ethiopia (2026) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67176-0 · Cited by 1,050
Cairns, M., Cisse, B., Sokhna, C., Cames, C., Simondon, K., Ba, E. H., Trape, J.-F., Gaye, O., Greenwood, B. M., & Milligan, P. J. M. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01161-09 · Cited by 26 · cited 1×
“21 These tolerability issues are acute GI effects and, therefore, associated with poor local GI tolerability of high doses or with high peak concentrations, rather than with high total systemic exposures.”
Research works printed but not linked: 15
- 10.1056/NEJMoa1314981 · DOI · Paper page
- 10.1056/NEJMoa0808859 · DOI · Paper page
- 10.1016/S1473-3099(15)00487-9 · DOI · Paper page
- 10.1128/AAC.00835-15 · DOI · Paper page
- 10.1038/s41579-024-01008-2 · DOI · Paper page
- 10.1016/S0140-6736(20)30552-3 · DOI · Paper page
- 10.1016/S1473-3099(21)00692-7 · DOI
- 10.1016/S1473-3099(15)70024-1 · DOI
- 10.1186/s12916-015-0301-z · DOI
- 10.1128/AAC.02193-17 · DOI
- 10.1371/journal.pmed.1002579 · DOI
- 10.1128/AAC.01140-19 · DOI
- 10.1016/j.trstmh.2005.09.021 · DOI
- 10.1086/503423 · DOI · Paper page
- 10.1093/cid/cis958 · DOI
Cited by
Letebo, A., Vanheer, L. N., Engdaw, M., Ejigu, L. A., Hailu Alemayehu, D., Deressa, J. D., Adnew, B., Ayele, A., Bezabih, M. K., Demisse, M., et al. (2026) · Nature Microbiology · doi:10.1038/s41564-026-02420-5 · Cited by 4
Metadata
- Authors
- Tarning, J., White, N. J., & Dondorp, A. M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2025-02-12
- Volume
- 117
- Issue
- 5
- Pages
- 1248-1253
- ISSN
- 0009-9236
- 1532-6535
- Cited by
- 5
- References
- 2
- Language
- en
- Funders
- Wellcome Trust (220211)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dose‐Optimization of a Novel Co‐Formulated Triple Combination Antimalarial Therapy: Artemether‐Lumefantrine‐Amodiaquine. https://app.cochat.ai/papers/10.1002/cpt.3582
- The paper
- Tarning, J., White, N. J., & Dondorp, A. M. (2025). Dose‐Optimization of a Novel Co‐Formulated Triple Combination Antimalarial Therapy: Artemether‐Lumefantrine‐Amodiaquine. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3582
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.